Abstract
Beneficial chemotherapy programs along with improved supportive care methods promoted acute lymphoblastic leukemia (ALL) from fatal to potentially curable disease. Leukemogenesis study and prognostic factor analysis became the basis for identification of prognostic groups and design of riskadapted chemotherapy for ALL. One of the modern treatment protocols for ALL is ALL IC-BFM 2002, its treatment results are presented in the current article. This protocol occurs to be highly-effective and results in high long-term survival rates: 10-year overall survival was 90,4±2,6%, event-free — 82,5±3,4%, and relapse-free — 87,3±3,1%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
